Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve

Sponsor: King's College Hospital NHS Trust

NCT ID: NCT06572215

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Dapagliflozin (drug)
How long the study runs
Study runs about 48 months (dates as stated)
About the drug or intervention
Dapagliflozin — drug: On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
40 Years and over
Who
All
Number of participants
44
Started
2023-12-14
Last checked
2026-03

Plain English Summary

What is this study?

  • • Testing a new treatment for chronic kidney diseases
  • • Clinical study - 44 participants
  • • This is a feasibility study to assess new, more practical ways of measuring renal reserve

Who can take part?

  • • Ages 40 Years and over
  • • Diagnosed with chronic kidney diseases

Where?

  • • London - King's College Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

This is a feasibility study to assess new, more practical ways of measuring renal reserve.

More detail

Quantification of glomerular filtration rate (GFR) over time is the standard assessment of kidney function. In clinical practice, the endogenous marker, 'serum creatinine' concentration, is used as a static assessment of kidney function to estimate GFR. However, serum creatinine fails to increase until at least 50% of kidney tissue is lost,\[2\] thus is an inadequate indicator of early CKD. GFR like many other physiological processes is not static and augments temporarily to stimuli such as exercise and protein intake, by up to 25% from baseline in healthy individuals.\[3\] Similar to cardiac function stress tests which predict adverse outcomes, inability to respond to renal stressors or 'reduced renal reserve' has been demonstrated to occur prior to development of CKD (e.g. in patients with diabetes and previous acute kidney injury (AKI)) and is associated with vulnerability to future AKI, despite the presence of apparently normal kidney function measured by serum creatinine concentration.\[4\] Renal reserve is lost with progressive CKD,\[4\] and has also been demonstrated to relate to severity of histological lesions.\[5\] Current measurements of renal reserve (stimulated increase in GFR due to augmented renal blood flow above basal fasting values) involve administration of a compound that is freely filtered by the glomerulus, unaffected by tubular function and is physiologically inert, with assessment before and after an oral protein load or amino acid infusion which induces arterial vasodilation, increasing renal blood flow and GFR The study proposes a comparison of two novel methods of 'dynamic renal function testing' with renal reserve testing.

Chronic Kidney Diseases

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 40 Years and over
  • Who can join: All genders

Biomarkers mentioned

eGFR

What the study is looking for

  • ✓Inclusion:
  • ✓Patients with sickle cell nephropathy, diagnosed clinically or histologically. Sickle Cell patients will be...
  • ✓Previous living kidney donation
  • ✓Age ≥ 4No safety concern or known allergy to any trial medications.
  • ✓Willing and able to provide written agreement to take part
See the full criteria
Inclusion: * Patients with sickle cell nephropathy, diagnosed clinically or histologically. Sickle Cell patients will be confirmed Hb SS and eGFR (CKD-EPI) ≥ 135 ml/min/1.73m2 OR * Previous living kidney donation * Age ≥ 4No contraindication or known allergy to any trial medications. * Willing and able to provide written informed consent Exclusion: * Aged \< 40 * Unable or unwilling to provide informed consent * Breastfeeding or pregnant women * Patients involved in other interventional research studies.

Where Is This Study? (1 UK site)

King's College Hospital

London, United Kingdom

Recruiting
Site contact (verified)

How to Get in Touch

Kate Bramham, Doctor

Sponsor contact

CONTACT

0203 299 9000 kch-tr.research@nhs.net
Data sourced from ClinicalTrials.gov · Last verified: 2026-03